European Biosimilars Market Opportunity Outlook Report 2015-2020

Biosimilars have been introduced for several disease categories offering myriad of options to the patients. Cancer supportive therapies have large consumer base due to which associated biosimilars are in high demand. Filgrastim and Erythropoietins biosimilars are one of the widely used products in European market. These well-established segments have numbers of products as compared to other disease categories. Biosimilar monoclonal antibodies are in high demand as they have high safety and efficacy along with minimized side effects. Their cost is also lesser as compared to biologic monoclonal antibodies.

Besides this, biosimilar insulin has also been introduced which have capability to generate significant revenues. Biosimilar insulin has created as new segment due to which more biosimilar products are expected to enter in coming years. In this way, European biosimilars market shows diverse categories and opportunities to venture in newly developed segments.

Extrapolation of biosimilars is allowed after establishing significant comparability with reference biologics. Depending on quality profile they are approved by EMA and biosimilar developers have to submit Risk Management Plan (RMP). This measure ensures that biosimilars entering in European market are harmless. Biosimilar developers from developing countries find it difficult to enter in European market as their fall short of EMA's standards.

On the other hand, outsourced biosimilars products showing compliance with EMA's norms are allowed for commercialization. In this way, biosimilar developers from under developing countries find Europe as a suitable market place. Their competitive prices and highly developed manufacturing capabilities have also contributed in growth of European biosimilars market.

Europe Biosimilars Market Opportunity Outlook 2020 Report Highlight:

- Europe Biosimilars Market Outlook
- Europe Biosimilars Market Trend Analysis by Country
- Introduction of Biosimilars in European Market by Segment
- Clinical & Non Clinical Guidelines
- Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase
- Europe Biosimilar Clinical Pipeline: 109 Biosimilars
- Clinical Insight of Biosimilars Marketed in Europe
- Marketed Biosimilars in Europe: 20 Biosimilars

Key Topics Covered:

1. Europe Biosimilars Market Outlook

2. Europe Biosimilars Market Trend Analysis by Country

3. Introduction of Biosimilars in European Market by Segment

4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario

5. Europe Biosimilars Market Dynamics

6. Europe Biosimilars Market Future Outlook

7. Europe Biosmilars Market Regulatory Framework

8. Clinical & Non Clinical Guideline For Development of Biosimilars in Europe

9. Europe Biosimilar Clinical Pipeline by Country, Company, Indication & Phase

10. Clinical Insight of Biosimilars Marketed in Europe

11. Suspended & Discontinued Biosimilars Clinical Insight

12. Competive Landscape

- Allergan
- Alvotech
- Amgen
- Biocad
- Bio-Ker
- BioXpress Therapeutics
- Boehringer Ingelheim
- Celltrion
- Cerbios Pharma
- Gedeon Richter
- Genentech
- Genexine
- Glycotope
- Harvest Moon Pharmaceuticals
- Hospira
- Janssen Biotech
- LFB Biotechnologies
- Mabion
- mAbxience
- Merck
- Momenta
- Novartis
- Perosphere
- Pfizer
- Pharmaceuticals
- Reliance Life Sciences
- Roche
- R-Pharm
- Samsung Bioepis
- Sanofi
- Teva Pharmaceutical
- Wockhardt

For more information visit http://www.researchandmarkets.com/research/944mqr/europe

CONTACT: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Biosimilars and Biosuperiors